• DOI:10.1056/nejmoa2204619
• Corpus ID: 249352736

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

@article{Jnne2022AdagrasibIN,
  title={Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.},
  author={Pasi A. J{\"a}nne and Gregory Riely and Shirish M. Gadgeel and Rebecca S. Heist and S-H.I. Ou and Jose Maria Pacheco and Melissa L. Johnson and Joshua K. Sabari and Konstantinos Leventakos and Edwin Yau and Lyudmila Bazhenova and Marcelo Vailati Negr{\~a}o and Nathan A. Pennell and Jun Zhang and Kenna Anderes and Hirak Der-Torossian and Thian San Kheoh and Karen Velastegui and Xiao Qiang Yan and James G. Christensen and Richard C. Chao and Alexander I. Spira},
  journal={The New England journal of medicine},
  year={2022}
}

• P. Jänne, Gregory Riely, +19 authors A. Spira
• Published 3 June 2022
• Medicine
• The New England journal of medicine

BACKGROUND
Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study.

METHODS
In a registrational phase 2 cohort, we evaluated adagrasib (600 mg orally twice daily) in patients with KRASG12C -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety.

RESULTS
As of October 15, 2021, a total of 116 patients with KRASG12C -mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients - grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) - and resulted in drug discontinuation in 6.9% of patients.

CONCLUSIONS
In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).